Tests cevostamab with pomalidomide and dexamethasone in previously treated multiple myeloma
Tests cevostamab plus pomalidomide and dexamethasone against standard care in adults with myeloma.
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Guangzhou, Hangzhou, Jinan, Kunming, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, and Wuhan, ChinaSee the 14 sitesAlso in 17 other countries, 99 sites
- Trial code
- Registry title
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 380 people, planned
- Started
- 23 Jun 2026
- Expected to end
- 31 Jan 2033
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cevostamab
- Pomalidomide
- Dexamethasone
- Daratumumab
- Elotuzumab
- Carfilzomib
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma who have had one to three earlier lines of treatment, including an anti-CD38 antibody or lenalidomide. It compares cevostamab with pomalidomide and dexamethasone against standard care.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma diagnosed by the International Myeloma Working Group criteria, with measurable disease at screening. Activity level (ECOG) of 0 or 1; ECOG 2 is allowed if it is only due to local myeloma symptoms such as pain.
- Earlier treatment
- One to three earlier lines of treatment, including at least two consecutive cycles of a regimen with an anti-CD38 therapy or a regimen with lenalidomide.
Main reasons for not taking part
- Known history of systemic light chain amyloidosis with major organ involvement
- Known history or current plasma cell leukemia
- Stomach or bowel disease that could change how oral drugs are absorbed
- Any ongoing disease of the central nervous system
- Non-secretory myeloma
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment
- Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible
- MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
- Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide
- Participants must have measurable disease during screening
Who cannot take part
- GI disease that might significantly alter absorption of oral drugs
- Participants must not have any ongoing CNS disease or non-secretory myeloma
- Known history of systemic light chain amyloidosis with major organ involvement (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
- Known history or current plasma cell leukemia
Where in China
Also in 17 other countries, 99 sites
- Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaTaking people
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
- The First Affiliated Hospital, Zhejiang University School of Medicine - Qingchun Campus - PPDSHangzhou, ChinaTaking people
- Qilu Hospital of Shandong UniversityJinan, ChinaTaking people
- The First Affilliated Hospital of Kunming Medical UniversityKunming, ChinaTaking people
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical SchoolNanjing, ChinaTaking people
- The First Affiliate Hospital of Guangxi Medical UniversityNanning, ChinaTaking people
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaTaking people
- Renji Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
- The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaTaking people
- Tianjin Institute of Hematology & Blood Diseases HospitalTianjin, ChinaTaking people
- The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaTaking people
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
About the trial
What the trial wants to find out
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
The 2 groups in the trial
- Cevostamab + Pomalidomide + DexamethasoneTreatment being tested
Cevostamab will be administered intravenously on a 21-day cycle in cycle 1 and on a 28-day cycle from cycle 2 onwards. Pomalidomide will be administered orally (PO) on a 28-day cycle from cycle 2 onwards. Dexamethasone will be administered as a premedication prior to cevostamab.
Treatment: Cevostamab, Pomalidomide, and Dexamethasone
- Standard of Care (SOC)Existing treatment, for comparison
Participants will receive investigator's choice of one SOC regimen.
Treatment: Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab, and Carfilzomib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
- Plain-language title
- Tests cevostamab with pomalidomide and dexamethasone in previously treated multiple myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Record updated
- 10 November 2026